Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.15 USD | +0.23% | +0.43% | -7.50% |
Feb. 28 | Inhibrx Shares Fall After Q4 Net Loss Widens | MT |
Feb. 28 | Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M | MT |
Business Summary
Number of employees: 169
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biological Therapeutic Candidates
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | -17.88% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | -17.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brendan Eckelman
FOU | Founder | 45 | 10-03-31 |
Mark Lappe
CEO | Chief Executive Officer | 57 | 10-03-31 |
Kelly Deck
DFI | Director of Finance/CFO | 44 | 18-09-30 |
Robert Boothroyd
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Vasily Andrianov
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Ashraf Amanullah
CTO | Chief Tech/Sci/R&D Officer | 56 | 18-07-31 |
Jeffrey Jensen
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Charbel Helaihel
SAM | Sales & Marketing | - | 23-01-31 |
David Kao
LAW | General Counsel | - | 21-10-27 |
Leah Pollema
LAW | General Counsel | - | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Kayyem
BRD | Director/Board Member | 60 | 18-03-31 |
Mark Lappe
CEO | Chief Executive Officer | 57 | 10-03-31 |
Kimberly Manhard
BRD | Director/Board Member | 64 | 20-05-31 |
Doug Forsyth
BRD | Director/Board Member | 55 | 18-03-31 |
Kristiina Vuori
BRD | Director/Board Member | 56 | 21-10-27 |
Brendan Eckelman
FOU | Founder | 45 | 10-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 47,392,447 | 33,760,797 ( 71.24 %) | 0 | 71.24 % |
Company contact information
Inhibrx, Inc.
11025 North Torrey Pines Road Suite 200
92037, La Jolla
+858 795 4220
http://www.inhibrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.50% | 1.67B | |
+2.56% | 108B | |
+10.02% | 104B | |
+8.21% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |
- Stock
- Equities
- Stock Inhibrx, Inc. - Nasdaq
- Company Inhibrx, Inc.